Mode
Text Size
Log in / Sign up

Energy therapies improve exercise capacity and quality of life in patients with chronic obstructive pulmonary diseaseEnergy Therapies May Improve Quality of Life for COPD Patients

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider energy therapies as a complementary approach to improve exercise capacity and quality of life in COPD patients.

This meta-analysis synthesized data from 8 randomized controlled trials to evaluate the impact of energy therapies on patients with chronic obstructive pulmonary disease (COPD). The primary focus was on pulmonary function metrics, including FEV1, FVC, and FEV1/FVC ratios. Secondary outcomes included exercise capacity measured by the 6-Minute Walking Test (6MWT) and quality of life assessed via the St George's Respiratory Questionnaire (SGRQ).

The meta-analysis found that energy therapies did not result in significant improvements to pulmonary function, with p-values greater than 0.05 for FEV1, FVC, and FEV1/FVC values. However, patients showed significant improvement in 6MWT scores (95% CI, P <.05) and improved quality of life on SGRQ scores due to reduced stress and anxiety.

The authors noted several limitations, including methodological variations and differences in sample sizes across the included trials. They emphasized that large-scale, long-term randomized controlled trials are necessary to clarify the impact of these therapies on pulmonary function. Clinically, energy therapies may serve as a complementary approach to improve exercise capacity and quality of life in COPD patients, though they do not appear to alter primary lung function metrics.

How this fits prior evidence

This meta-analysis addresses a gap in non-pharmacological interventions for COPD by evaluating energy therapies. While it does not replace the established role of inspiratory muscle training to improve muscle strength and exercise tolerance, it suggests that energy therapies may specifically target quality of life and stress reduction. It also complements existing knowledge regarding the impact of various factors on COPD risk and outcomes.

Researchers looked at eight different clinical trials to see how energy therapies affect people with chronic obstructive pulmonary disease (COPD). The study focused on whether these treatments could help with breathing, physical activity, and overall well-being.

The results showed that patients who received energy therapies reported better exercise capacity during a six-minute walk. They also reported a better quality of life because the treatments helped reduce feelings of stress and anxiety. However, the study did not find any significant improvements in actual lung function measurements like FEV1 or FVC.

While these findings are encouraging for patient comfort, it is important to note that the study had some limitations, such as differences in how each trial was conducted. Because the results on lung function were not clear, more large-scale studies are needed. For now, energy therapies may serve as a helpful way to manage symptoms and improve daily life alongside standard medical care.

What this means for you:
Energy therapies may help COPD patients feel less stressed and walk further, but they do not change lung function.

Common questions

Can energy therapies help me breathe better if I have COPD?

The study found that while energy therapies did not significantly improve lung function measurements like FEV1 or FVC, they did help patients feel better. Specifically, these therapies were linked to reduced stress and anxiety, which can make managing a chronic condition like COPD much easier for many people.

Will these treatments help me walk further?

Yes, the research showed a significant improvement in 6-minute walking test scores for patients using energy therapies. This suggests that these methods may help improve your exercise capacity and physical stamina while living with chronic obstructive pulmonary disease.

Is it safe to use energy therapy for COPD?

The study did not report any specific adverse events or safety concerns regarding the use of energy therapies. However, because these results are from a meta-analysis of eight trials, you should talk to your doctor to see how these therapies can safely fit into your personal treatment plan.

Study Details

Study typeMeta analysis
EvidenceLevel 1
View Original Abstract ↓
This systematic review and meta-analysis evaluate the effects of energy therapies on pulmonary function (forced expiratory volume in 1 second [FEV1], forced vital capacity [FVC], and FEV1/FVC), exercise capacity (6-Minute Walking Test [6MWT]), and quality of life (St George's Respiratory Questionnaire [SGRQ]) in chronic obstructive pulmonary disease (COPD) patients. Conducted per PRISMA guidelines and registered in PROSPERO, this meta-analysis included 8 randomized controlled trials (RCTs) identified through systematic searches of Web of Science, PubMed, Google Scholar, EBSCO, Embase, and Cochrane Library (June 2024-January 2025). Data were analyzed using Comprehensive Meta-Analysis Version 3 software, with heterogeneity and publication bias assessments. Energy therapies significantly improved 6MWT scores (95% CI, P < .05) and SGRQ scores, enhancing quality of life. Patients receiving energy therapy showed increased walking distance, particularly when combined with pulmonary rehabilitation. SGRQ results indicated better quality of life, mainly due to reduced stress and anxiety. However, no significant improvement was found in FEV1, FVC, or FEV1/FVC values ( P > 0.05), suggesting limited direct effects on pulmonary function. Methodological variations and sample size differences contributed to result inconsistencies. Energy therapies may complement COPD treatment by improving exercise capacity and quality of life. However, large-scale, long-term RCTs are needed to clarify their impact on pulmonary function.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.